1. Home
  2. FSLR vs UTHR Comparison

FSLR vs UTHR Comparison

Compare FSLR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Solar Inc.

FSLR

First Solar Inc.

HOLD

Current Price

$212.10

Market Cap

23.8B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$529.68

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSLR
UTHR
Founded
1999
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.8B
25.1B
IPO Year
2006
1999

Fundamental Metrics

Financial Performance
Metric
FSLR
UTHR
Price
$212.10
$529.68
Analyst Decision
Buy
Buy
Analyst Count
27
14
Target Price
$236.42
$567.57
AVG Volume (30 Days)
1.7M
449.6K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
18.22
13.07
EPS
3.22
5.82
Revenue
$5,219,376,000.00
$1,483,300,000.00
Revenue This Year
$1.43
$6.39
Revenue Next Year
$16.77
$14.18
P/E Ratio
$69.92
$90.84
Revenue Growth
24.09
2.38
52 Week Low
$171.86
$272.18
52 Week High
$320.95
$609.35

Technical Indicators

Market Signals
Indicator
FSLR
UTHR
Relative Strength Index (RSI) 34.32 40.16
Support Level $185.64 $464.92
Resistance Level $248.75 $542.66
Average True Range (ATR) 10.67 13.00
MACD -1.97 -1.76
Stochastic Oscillator 2.73 22.06

Price Performance

Historical Comparison
FSLR
UTHR

About FSLR First Solar Inc.

First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: